RECOVERY / SINGLE
KPV
10MGThis content is intended for educational and research reference only and does not constitute medical advice, diagnosis, or treatment. Experimental compounds are for research use only and are not for human consumption. Always consult qualified healthcare providers before starting any therapy.
Research Overview
The C-terminal tripeptide sequence of alpha-MSH, studied for anti-inflammatory research without the parent hormone's melanotropic effects.
Available Strengths
- 10MG (KP10)
Research Protocol
Reference gradual schedule
| Period | Dose | U-100 units | Volume |
|---|---|---|---|
| Week 1 | 0.2 mg | 6 | 0.06 mL |
| Week 2 | 0.3 mg | 9 | 0.09 mL |
| Week 3 | 0.4 mg | 12 | 0.12 mL |
| Weeks 4–8 | 0.5 mg | 15 | 0.15 mL |
Reconstitution
≈3.33 mg/mL once reconstituted
- Draw 3.0 mL of bacteriostatic water per 10 mg vial.
- Inject slowly along the vial wall; swirl gently until dissolved.
Research context
Discussed in the cited research as reducing pro-inflammatory cytokine activity and modulating immune responses through NF-κB signalling inhibition.
Storage
−20°C or below, protected from moisture and light. 2–8°C, use within ~30 days, avoid freeze-thaw cycles.
Research Notes
- For educational and research reference only. Not medical advice and not intended for unsupervised human use.
References
Source reference: PeptideDosages.com · 2026-08-18 · Exact strength match with the cited source